BRAF and melanoma: Our findings demonstrate that targeting mitochondria with DSF shows significant suppression efficacy in BRAFi-resistant melanoma cells, suggesting the combination of DSF with BRAF inhibitors may be a promising strategy to overcome BRAFi resistance.